These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32407801)

  • 21. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study.
    Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
    QJM; 2016 Mar; 109(3):167-73. PubMed ID: 26031706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
    Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
    Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
    Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y
    Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
    Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
    Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
    Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
    Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
    Akahori D; Inoue Y; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Suda T
    Sci Rep; 2021 Jul; 11(1):14999. PubMed ID: 34294857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis.
    Yuan H; Zhu ZZ; Lu Y; Liu F; Zhang W; Huang G; Zhu G; Jiang B
    Yonsei Med J; 2012 Jan; 53(1):132-7. PubMed ID: 22187243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
    Tseng JS; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Chen JJ; Chang GC
    J Thorac Oncol; 2015 Apr; 10(4):603-10. PubMed ID: 25514801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.
    Assi H; Tfayli A; Assaf N; Daya SA; Bidikian AH; Kawsarani D; Fermanian P; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Aug; 46(4):3671-3676. PubMed ID: 31147859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
    Qian X; Liu J; Sun Y; Wang M; Lei H; Luo G; Liu X; Xiong C; Liu D; Liu J; Tang Y
    Oncotarget; 2016 May; 7(20):29154-65. PubMed ID: 27081078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
    Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
    Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
    Sánchez-Font A; Chalela R; Martín-Ontiyuelo C; Albero-González R; Dalmases A; Longarón R; Alonso-Espinaco V; Curull V; Bellosillo B; Pijuan L
    Cancer Cytopathol; 2018 Oct; 126(10):860-871. PubMed ID: 30291816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens.
    Matsuo Y; Yoshida T; Yamashita K; Satoh Y
    Cancer Cytopathol; 2018 Dec; 126(12):1011-1021. PubMed ID: 30343520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
    Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma.
    Zhang P; Wu X; Tang M; Nie X; Li L
    Thorac Cancer; 2019 Dec; 10(12):2218-2224. PubMed ID: 31602787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
    Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma.
    Shi C; Zheng Y; Li Y; Sun H; Liu S
    J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28670719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.